Ricardo D. Parrondo

Jul 22, 2024 | nature.com | Matthew Rees |Radhika Bansal |Sikander Ailawadhi |Ricardo D. Parrondo |Saurabh Chhabra |Angela Dispenzieri | +9 more

AbstractThree classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018-2023.

Mar 28, 2024 | onclive.com | Ricardo D. Parrondo

Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic, discusses the implications of findings from the phase 3 CARTITUDE-4 trial (NCT04181827) of ciltacabtagene autoleucel (cilta-cel; Carvykti) in lenalidomide (Revlimid)–refractory multiple myeloma. CARTITUDE-4 compared cilta-cel with standard-of-care (SOC) therapy in patients with lenalidomide-refractory multiple myeloma who had received between 1 and 3 prior lines of therapy.

Feb 14, 2024 | onclive.com | Ricardo D. Parrondo

Ricardo D. Parrondo, MD, hematologist/oncologist, assistant professor, Mayo Clinic, discusses the ongoing exploration of teclistamab-cqyv (Tecvayli) and talquetamab (Talvey) in the phase 1b/2 RedirecTT-1 trial (NCT04586426) in patients with relapsed/refractory multiple myeloma.

Feb 7, 2024 | onclive.com | Ricardo D. Parrondo

Ricardo D. Parrondo, MD, hematologist/oncologist, assistant professor, Mayo Clinic, discusses the exploration of the non-BCMA CAR T-cell target GPRC5D in multiple myeloma. GPRC5D has emerged as a new target of interest within multiple myeloma, sparking interest in the development of novel CAR T-cell products and bispecific antibodies targeting this antigen, Parrondo begins.

Oct 23, 2023 | onclive.com | Ricardo D. Parrondo

October 23, 2023Ricardo D. Parrondo, MD, discusses the current treatment landscape of mantle cell lymphoma and highlights ongoing areas of investigation in other hematologic malignancies. Ricardo D. Parrondo, MD, hematologist/oncologist, assistant professor, Mayo Clinic, discusses the current treatment landscape of mantle cell lymphoma (MCL) and highlights ongoing areas of investigation in other hematologic malignancies.